Avance

Avance Clinical is a full-service global Contract Research Organization (CRO) with more than 30 years of experience accelerating drug development for biotech innovators worldwide. Headquartered in Australia, with operations across Australia, New Zealand, the United States, Asia, and Europe, Avance specialise in early-phase to proof-of-concept clinical trials across oncology, CNS, renal and cardiometabolic disorders, rare diseases, and advanced therapies including cell and gene treatments. Our Global model enables biotechs to leverage Australia’s streamlined regulatory environment — no IND requirement, ethics approval within 5–6 weeks, and up to 43.5% R&D tax rebate — to generate high-quality, cost-efficient early data accepted
by the EMA, FDA, and other major regulators. Through our GlobalReady™ framework, we ensure seamless scientific and operational continuity from first-in-human studies through multi-regional Phase II/III programs with access to Asia Pacific and North America, reducing development risk, accelerating timelines, and preserving capital for biotech innovators pursuing global market success.